NEW YORK, March 26 - LumiCyte of Fremont, Calif. has obtained $20 million in private venture capital to fund its protein biochip program, the company said Monday.

The financing round, which follows the company's initial $5 million fundraising effort last year, was led by Tullis-Dickerson & Co., with additional funding from OrbiMed Advisors and Redleaf Group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.